iSelect Fund
  • Portfolio
  • Team
  • Focus Areas
    • Food & Agriculture
    • Healthcare
    • Food is Health
    • Soil Health
    • Impact Investing
    • Entrepreneurs
  • Invest
  • Insights
  • Contact
  • My iSelect
    • My iSelect Login
Select Page

CLS’ PRODUCTS AND METHOD ARE PLANNED TO BE USED IN A CLINICAL TRIAL, CARRIED OUT BY IMMUNOPHOTONICS, REGARDING EVALUATION OF NEW DRUG

Read more
Immunophotonics, SAKK Move Forward with Research Collaboration

Immunophotonics, SAKK Move Forward with Research Collaboration

Cancer care is entering a new age, transitioning from treatments that attack both cancerous and healthy cells at the same time, to more targeted, specialized therapies that address the root cause of cancer itself without damaging surrounding tissues. Biotech company... Read more
American Entrepreneur – Immunophotonics

American Entrepreneur – Immunophotonics

iSelect sat down with Immunophotonics CEO Lu Alleruzzo to talk about immunotherapy and innovations in the treatment of cancer

Read more
Next Entries »

Related Posts

  • startups
    Empowering Entrepreneurs and Their Success
  • what investors look for
    This Is What the Ideal iSelect Company Looks Like
  • David Yocom
    David Yocom, Venture for America Fellow, Joins iSelect Ventures Team
  • iSelect 101: Funding Midwestern Entrepreneurs
  • Start of iSelect Fund
    How iSelect Got Its Start
AgTechFund BLOG SIDEBAR

(314) 219-8688

7750 Maryland Ave
Box 11826
St. Louis, MO 63105

Crunchbase   Twitter   LinkedIn   Facebook   YouTube

Securities offered through North Capital Private Securities ("NCPS"), Member FINRA/SIPC, located at 623 East Ft. Union Blvd, Suite 101, Salt Lake City, UT 84047. NCPS does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform.  Please review North Capital’s Form CRS and its background on FINRA’s BrokerCheck.  Investments in private offerings are speculative, illiquid and involve a high degree of risk and those investors who cannot afford to lose their entire investment and who cannot hold an investment for an indeterminate period should not invest in such offerings. Past performance is not indicative of future results.  All information provided herein should not be relied upon to make an investment decision and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Prospective investors are recommended to consult with a financial adviser, attorney, accountant, and any other professional that can help you understand and assess the risks associated with an investment opportunity. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.